1. Muduma, G., et al., Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant. PLoS One, 2016. 11(11): p. e0160421.
2. Henry, M.L., Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant, 1999. 13(3): p. 209-20.
3. Ojo, A.O., et al., Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med, 2003. 349(10): p. 931-40.
4. Wilkinson, A. and P.T. Pham, Kidney dysfunction in the recipients of liver transplants. Liver Transpl, 2005(11 Suppl 2): p. S47-51.
5. O'Riordan, A., et al., Acute renal disease, as defined by the RIFLE criteria, post- liver transplantation. Am J Transplant, 2007. 7(1): p. 168-76.
6. Lassnigg, A., et al., Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? Crit Care Med, 2008. 36(4): p. 1129-37.
7. Yalavarthy, R., C.L. Edelstein, and I. Teitelbaum, Acute renal failure and chronic kidney disease following liver transplantation. Hemodial Int, 2007. 11 Suppl 3: p. S7-12.
8. Bonventre, J.V., et al., Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol, 2010. 28(5): p. 436-40.
9. Sieber, M., et al., Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicol Sci, 2009. 109(2): p. 336-49.
10. Khwaja, A., KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract, 2012. 120(4): p. c179-84.
11. Bellomo, R., J.A. Kellum, and C. Ronco, Acute kidney injury. Lancet, 2012. 380(9843): p. 756-66.
12. Lewandowska, L., J. Malyszko, and J. Joanna Matuszkiewicz-Rowinska, Urinary and Serum Biomarkers for Prediction of Acute Kidney Injury in Patients Undergoing Liver Transplantation. Ann Transplant, 2019. 24: p. 291-297.
13. Wagener, G., et al., Urinary neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury after orthotopic liver transplantation. Nephrol Dial Transplant, 2011. 26(5): p. 1717-23.
14. Mishra, J., et al., Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. The Lancet, 2005. 365(9466): p. 1231-1238.
15. Hishikari, K., et al., Urinary Liver-Type Fatty Acid-Binding Protein Level as a Predictive Biomarker of Acute Kidney Injury in Patients with Acute Decompensated Heart Failure. Cardiorenal Med, 2017. 7(4): p. 267-275.
16. Nishihara, K., et al., Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin- induced nephrotoxicity. Biochem Pharmacol, 2013. 85(4): p. 570-82.
17. Shinke, H., et al., Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemother Pharmacol, 2015. 76(5): p. 989-96.
18. Tsuchimoto, A., et al., Urinary neutrophil gelatinase-associated lipocalin: a useful biomarker for tacrolimus-induced acute kidney injury in liver transplant patients. PLoS One, 2014. 9(10): p. e110527.
19. Cullaro, G., et al., Early Postoperative Neutrophil Gelatinase-Associated Lipocalin Predicts the Development of Chronic Kidney Disease After Liver Transplantation. Transplantation, 2018. 102(5): p. 809-815.
20. Gu, Z., et al., Pharmacokinetics of free mycophenolic acid and limited sampling strategy for the estimation of area under the curve in liver transplant patients. Eur J Pharm Sci, 2012. 47(4): p. 636-41.
21. Schmeding, M., et al., Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial. Transplantation, 2011. 92(8): p. 923-9.
22. Neuberger, J.M., et al., Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant, 2009. 9(2): p. 327-36.
23. Hale, M.D., et al., The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther, 1998. 64(6): p. 672-83.
24. Kim, H., et al., Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation. Clin Mol Hepatol, 2014. 20(3): p. 291-9.
25. Jusko, W.J., et al., Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther, 1995. 57(3): p. 281-90.
26. Denton, M.D., C.C. Magee, and M.H. Sayegh, Immunosuppressive strategies in transplantation. Lancet, 1999. 353(9158): p. 1083-91.
27. Kahan, B.D., et al., Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther, 2002. 24(3): p. 330-50; discussion 329.
28. Brunet, M., et al., Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther Drug Monit, 2019. 41(3): p. 261-307.
29. Anglicheau, D., et al., Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics, 2007. 8(7): p. 835-49.
30. Goto, M., et al., CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics, 2004. 14(7): p. 471-8.
31. Haufroid, V., et al., CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant, 2006. 6(11): p. 2706-13.
32. Hesselink, D.A., et al., Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther, 2003. 74(3): p. 245-54.
33. Iwasaki, K., Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet, 2007. 22(5): p. 328-35.
34. Gomez-Bravo, M.A., et al., Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients. J Clin Pharmacol, 2013. 53(11): p. 1146-54.
35. Uesugi, M., et al., Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics, 2006. 16(2): p. 119-27.
36. Fluck, C.E., C. Nicolo, and A.V. Pandey, Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase. Fundam Clin Pharmacol, 2007. 21(4): p. 399-410.
37. Huang, N., et al., Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A, 2008. 105(5): p. 1733-8.
38. Hart, S.N. and X.B. Zhong, P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity. Expert Opin Drug Metab Toxicol, 2008. 4(4): p. 439-52.
39. de Jonge, H., et al., The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5- expressing renal recipients. Pharmacogenomics, 2011. 12(9): p. 1281-91.
40. Zhang, J.J., et al., The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Int J Clin Pharmacol Ther, 2015. 53(9): p. 728-36.
41. Masuda, S. and K. Inui, An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther, 2006. 112(1): p. 184-98.
42. Barri, Y.M., et al., Acute kidney injury following liver transplantation: definition and outcome. Liver Transpl, 2009. 15(5): p. 475-83.
43. Sherman, D.S., D.N. Fish, and I. Teitelbaum, Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis, 2003. 41(2): p. 269-78.
44. Wan, J., et al., Elevated serum concentrations of HE4 as a novel biomarker of disease severity and renal fibrosis in kidney disease. Oncotarget, 2016. 7(42): p. 67748-67759.
45. Nakagawa, S., et al., Molecular Markers of Tubulointerstitial Fibrosis and Tubular Cell Damage in Patients with Chronic Kidney Disease. PLoS One, 2015. 10(8): p. e0136994.
46. Nagy, B., Jr., et al., Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann Clin Biochem, 2012. 49(Pt 4): p. 377-80.
47. Yuan, T. and Y. Li, Human Epididymis Protein 4 as a Potential Biomarker of Chronic Kidney Disease in Female Patients With Normal Ovarian Function. Lab Med, 2017. 48(3): p. 238-243.
48. Zhu, F.X., et al., [Risk factors of renal failure in the early post-liver transplantation period]. Zhonghua Gan Zang Bing Za Zhi, 2005. 13(3): p. 168-70.
49. Iwata, H., et al., Negative prognostic impact of renal replacement therapy in adult living-donor liver transplant recipients: preoperative recipient condition and donor factors. Transplant Proc, 2014. 46(3): p. 716-20.
50. Miano, T.A., et al., Early Tacrolimus Concentrations After Lung Transplant Are Predicted by Combined Clinical and Genetic Factors and Associated With Acute Kidney Injury. Clin Pharmacol Ther, 2019.
51. Smoter, P., et al., Risk factors of acute renal failure after orthotopic liver transplantation: single-center experience. Transplant Proc, 2014. 46(8): p. 2786-9.
52. Whiting, P.H., et al., Experimental cyclosporin A nephrotoxicity. Br J Exp Pathol, 1982. 63(1): p. 88-94.
53. Murray, B.M., M.S. Paller, and T.F. Ferris, Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int, 1985. 28(5): p. 767-74.
54. Mohebbi, N., M. Mihailova, and C.A. Wagner, The calcineurin inhibitor FK506 (tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport proteins. Am J Physiol Renal Physiol, 2009. 297(2): p. F499-509.
55. Morgan, C., et al., Renal interstitial fibrosis in children treated with FK506 for nephrotic syndrome. Nephrol Dial Transplant, 2011. 26(9): p. 2860-5.
56. Kjeldsen, L., et al., Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem, 1993. 268(14): p. 10425-32.
57. Cowland, J.B. and N. Borregaard, Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics, 1997. 45(1): p. 17-23.
58. Hirsch, R., et al., NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol, 2007. 22(12): p. 2089-95.
59. Kuwabara, T., et al., Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int, 2009. 75(3): p. 285-94.
60. Bennett, M., et al., Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol, 2008. 3(3): p. 665- 73.
61. Gaspari, F., et al., Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case- control study. Nephron Clin Pract, 2010. 115(2): p. c154-60.
62. Mori, K., et al., Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest, 2005. 115(3): p. 610-21.
63. Clauss, A., H. Lilja, and A. Lundwall, A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J, 2002. 368(Pt 1): p. 233-42.
64. Bingle, L., et al., WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res, 2006. 7: p. 61.
65. Yang, Z., et al., Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis. Onco Targets Ther, 2013. 6: p. 957- 66.
66. LeBleu, V.S., et al., Identification of human epididymis protein-4 as a fibroblast- derived mediator of fibrosis. Nat Med, 2013. 19(2): p. 227-31.
67. Tajima, S., et al., Urinary Human Epididymis Secretory Protein 4 as a Useful Biomarker for Subclinical Acute Rejection Three Months after Kidney Transplantation. Int J Mol Sci, 2019. 20(19).
68. Pageaux, G.P., et al., Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl, 2006. 12(12): p. 1755-60.
69. Fukuda, M., et al., Neutrophil Gelatinase-Associated Lipocalin Is Not Associated with Tacrolimus-Induced Acute Kidney Injury in Liver Transplant Patients Who Received Mycophenolate Mofetil with Delayed Introduction of Tacrolimus. Int J Mol Sci, 2019. 20(12).
70. Kaltenborn, A. and H. Schrem, Mycophenolate mofetil in liver transplantation: a review. Ann Transplant, 2013. 18: p. 685-96.
71. Shipkova, M., et al., Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol, 1999. 126(5): p. 1075-82.
72. Bullingham, R.E., A.J. Nicholls, and B.R. Kamm, Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet, 1998. 34(6): p. 429-55.
73. Shaw, L.M. and I. Nowak, Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther Drug Monit, 1995. 17(6): p. 685-9.
74. Boudjema, K., et al., Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant, 2011. 11(5): p. 965-76.
75. Eckhoff, D.E., et al., Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation, 1998. 65(2): p. 180-7.
76. Jain, A., et al., A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl, 2002. 8(1): p. 40-6.
77. Staatz, C.E. and S.E. Tett, Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet, 2007. 46(1): p. 13-58.
78. Martial, L.C., et al., Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients. Pediatr Transplant, 2016. 20(4): p. 492-9.
79. Kawasaki, S., et al., Liver regeneration in recipients and donors after transplantation. Lancet, 1992. 339(8793): p. 580-1.
80. Jain, A., et al., Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients. J Clin Pharmacol, 2008. 48(5): p. 547-52.
81. Jain, A.B., et al., Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. Liver Transpl Surg, 1999. 5(2): p. 101-6.
82. Miura, M., et al., Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients. Ther Drug Monit, 2008. 30(1): p. 52-9.
83. Chen, H., et al., Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. Clin Pharmacokinet, 2007. 46(2): p. 175-85.
84. Bullingham, R., et al., Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol, 1996. 36(4): p. 315-24.
85. Kuypers, D.R., et al., Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol, 2010. 5(2): p. 341-58.
86. Hwang, S., et al., A clinical assessment of mycophenolate drug monitoring after liver transplantation. Clin Transplant, 2010. 24(2): p. E35-42.
87. Staatz, C.E., L.K. Goodman, and S.E. Tett, Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet, 2010. 49(4): p. 207-21.
88. Elens, L., et al., A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem, 2011. 57(11): p. 1574-83.
89. Barry, A. and M. Levine, A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients. Ther Drug Monit, 2010. 32(6): p. 708-14.
90. Suetsugu, K., et al., Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation. Int J Mol Sci, 2019. 20(10).
91. Ji, E., et al., Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. Transplantation, 2012. 94(8): p. 866-72.
92. Uesugi, M., et al., Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation. Pharmacogenet Genomics, 2014. 24(7): p. 356-66.
93. Cotreau, M.M., L.L. von Moltke, and D.J. Greenblatt, The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet, 2005. 44(1): p. 33-60.
94. Herrlinger, C. and U. Klotz, Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol, 2001. 15(6): p. 897-918.
95. Anderson, B.J. and N.H. Holford, Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol, 2008. 48: p. 303-32.
96. Sugawara, Y., et al., Correlation between optimal tacrolimus doses and the graft weight in living donor liver transplantation. Clin Transplant, 2002. 16(2): p. 102- 6.
97. Fukatsu, S., et al., Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol, 2001. 57(6-7): p. 479-84.
98. Wolbold, R., et al., Sex is a major determinant of CYP3A4 expression in human liver. Hepatology, 2003. 38(4): p. 978-88.
99. Lamba, V., et al., Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J Pharmacol Exp Ther, 2010. 332(3): p. 1088-99.
100. Yang, X., et al., Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res, 2010. 20(8): p. 1020-36.
101. Paine, M.F., et al., Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos, 2005. 33(3): p. 426-33.
102. Elens, L., et al., Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. Ther Drug Monit, 2014. 36(1): p. 71- 9.
103. Kuypers, D.R., et al., Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients. Pharmacogenet Genomics, 2014. 24(12): p. 597-606.
104. Phupradit, A., et al., Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation. Ther Drug Monit, 2018. 40(5): p. 549-557.
105. Lesche, D., et al., CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients. Ther Drug Monit, 2014. 36(6): p. 710-5.
106. Fu, R., et al., Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation. Acta Pharmacol Sin, 2019. 40(2): p. 151-159.
107. Gomes, A.M., et al., Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics, 2009. 10(4): p. 579-99.
108. Agrawal, V., et al., Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet Genomics, 2010. 20(10): p. 611-8.
109. Lunde, I., et al., The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol, 2014. 70(6): p. 685-93.
110. Oneda, B., et al., The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics, 2009. 19(11): p. 877-83.
111. Almeida-Paulo, G.N., et al., Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant. Pharmacogenomics J, 2018. 18(1): p. 180-186.
112. Cederbaum, A.I., Molecular mechanisms of the microsomal mixed function oxidases and biological and pathological implications. Redox Biol, 2015. 4: p. 60- 73.
113. Masuda, S., et al., Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther, 2000. 68(1): p. 98-103.
114. Masuda, S., et al., Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin Pharmacol Ther, 2006. 79(1): p. 90-102.
115. Hashida, T., et al., Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther, 2001. 69(5): p. 308-16.
論文の公開元へ
